Home › Forums › Main Forum › Media & News › Epclusa … Gilead’s Sofosbuvir/Valpatasvir

Viewing 5 posts - 1 through 5 (of 5 total)
  • Author
    Posts
  • 28 May 2016 at 2:59 pm #17978
    Avatar photoklhilde
    • Guardian Angel
    • ★★★★★
    @klhilde

    Epclusa, Gilead’s Sofosbuvir/Valpatasvir combo, appears to be close to approval in Europe and the target decision date in the US is June 28.

    http://finance.yahoo.com/news/european-chmp-adopts-positive-opinion-112500863.html

    Edit: Another report

    http://www.fiercebiotech.com/biotech/new-gilead-hep-c-combo-epclusa-gains-chmp-green-light

    BTW … Generic Valpatasvir is available from Mesochem. NOW.
    Mesochem has Velptasvir, but Dr. Freeman has pointed out that it is not in a readily absorbable form and is therefore unsuitable for home compounding.

    10 July 2016 at 12:25 pm #20775
    Avatar photorohcvfighter
    • Guardian Angel
    • ★★★★★
    @rohcvfighter

    Hi Everybody,

    looking at the information available about Velpatasvir and Ledipasvir, we can see that both are NS5A inhibitors.

    In my understanding, this means that they do action in similars ways in the replication process of the HCV virus …..

    So, let’s assume that one gets treated with Sofosbuvir+Ledipasvir and …will unfortunately relapse. Does it make any sense to get treated again, but this time with Sofosbuvir+Velpatasvir?

    P.S. perhaps it is a stupid question, but my logic got locked on this….

    Cheers,
    RHF

    In fiecare an HCV ucide peste 500000 oameni.Medicamentele generice pentru hepatita C functioneaza. Nu deveni statistica! Cauta pe Google “medicamente generice pentru hepatita C”.
    HCV kills more than 500000 people every year. HCV generic drugs work. Don’t become a statistic.
    By sharing this Youtube video you might save someone’s life!
    My TX: HEPCVIR-L[generic Harvoni]-India
    SVR52 achieved

    10 July 2016 at 12:33 pm #20777
    Avatar photoLondonGirl
    • Guardian Angel
    • ★★★★★
    @londongirl

    I’ve read somewhere, that it’s strong against RAVs, if I find the article, I will post.
    No doubt real world results should show a truer picture?

    GT1a Dec14 F2/8.7 VL 900000-2.5M
    Jan16 Hepcivir-L MonkMed/Redemption
    Baseline: VL 913575 Alt 76 Platelets low
    Wk2 VL1157 Alt 23
    DET Wk 8 VL 32 Alt19 ‘In the slow lane’
    June16 Fibro 5.7 F0/1 LIF 1.5
    Wk 11 VL<12 Alt 13 Det/Unq
    Extending tx 12 wks Mylan Sofo/Dac MonkMed
    Wk 14 VL <12 Det/Unq
    Wk 16 VL UNDETECTED
    Wk 22 + 4 Wks Sunprevir FixHepC
    Wk 24 UNDETECTED Alt 13
    Wk 12 post tx SVR12 Wk 26 SVR24
    Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC

    10 July 2016 at 5:46 pm #20783
    Avatar photomgalbrai
    • Guardian Angel
    • ★★★★★
    @mgalbrai

    Gilead’s Epclusa® – European Commission Grants Marketing Authorization

    http://hepatitiscnewdrugs.blogspot.com/2016/07/gileads-epclusa-european-commission.html?m=1

    Curehcvnow@gmail.com
    http://forums.delphiforums.com/generichcvtx

    G 1a F-1
    Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
    11/17/15 4 wk lab ALT 17 AST 16 <15
    11/18/15 Started Harvoni
    12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
    1/14/16 Fin. Tx
    7/07/16 UND SVR 24

    11 July 2016 at 9:27 pm #20831
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    Velpatasvir is more potent against certain RAVs

    Look at it this way. RAVs are like tolerance to alcohol, so while enough beer might still make you drunk scotch will do the job faster!

    YMMV

  • Author
    Posts
Viewing 5 posts - 1 through 5 (of 5 total)
  • You must be logged in to reply to this topic.